Resources and Tables Included in the App
Resources
Summary of lifestyle modifications that can be tried for at least 3 months before considering pharmacologic therapy for vasomotor symptoms: NAMS' MenoNotes on hot flashes (http://www.menopause.org/docs/for-women/mnflashes.pdf). Clinician may want to print this out for the patient (or email it via the app) as a handout.
NAMS Hormone Therapy Position Statement, 2012: available at: http://www.menopause.org/docs/default-documentlibrary/psht12.pdf?sfvrsn=2).
Personalized Estimation of the 10-Year Atherosclerotic Cardiovascular Disease Risk Score from the American College of Cardiology/American Heart Association (ACC/AHA ASCVD Risk Estimator) http://www.imedicalapps.com/2014/ 04/ascvd-risk-estimator-app/
Source: Goff DC, et al, Circulation 2013 (reference 10 above)
Figure displaying absolute risks of chronic disease outcomes by age group, Women's Health Initiative Hormone Therapy Trials: data from Manson JE, et al. JAMA 2013; 310:1353-1368 (reference 4 above).
NAMS Practice Pearl on Extended Duration Use of Hormone Therapy: Kaunitz A. (available online at: http://www. menopause.org/docs/default-source/2013/nams-practice-pearlextended-ht-duration.pdf)
Tables
Several tables adapted from Menopause Practice: A Clinician's Guide, 5th edition, NAMS, 2014*, including:
Table 1 . Vaginal Estrogen Therapy Products for Postmenopausal Use in the United States and Canada (detailed listing of products, composition, and dosages)
Table 2. Oral Estrogen Therapy Products for Postmenopausal Use in the United States and Canada (detailed listing of products, composition, and dosages [categories of low, moderate, and high])
Table 3. Transdermal Estrogen Therapy Products for Postmenopausal Use in the United States and Canada (patches, gels, emulsions, and sprays: detailed listing of products, composition, and dosages [categories of low, moderate, and high])
Table 4. Approximate Equivalent Estrogen Doses for Postmenopausal Use (oral and transdermal formulations)
Table 5. Combination Estrogen-Progestogen Therapy Products for Postmenopausal Use in the United States and Canada (oral continuous-cyclic, oral continuouscombined, oral intermittent-combined, and transdermal continuous-combined regimens)
Table 6. Progestogens Available in the United States and Canada (Detailed listing of products, composition, and dosages)
Table 7. Estrogen-Progestogen Therapy Regimens, Terminology (sequential, continuous-combined, intermittent-combined)
Table 8. Minimum Progestogen Dosing Requirements for Endometrial Protection With Standard Estrogen Dosing
Table 9. FDA-approved "Bioidentical" Hormone Products (FDA-approved products containing estradiol and/or progesterone)
Table 10. Pros and Cons of Hormone Therapy Routes of Administration (oral, transdermal, vaginal)
*Note that information on hormone therapy formulations and dosages is regularly updated on the NAMS website at: http://www.menopause.org/docs/default-source/2014/namsht-tables.pdf).